Published in Int J Cancer on September 01, 2010
Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays. PLoS One (2015) 1.40
The role of shear stress in Blood-Brain Barrier endothelial physiology. BMC Neurosci (2011) 1.25
Histone deacetylases as targets for treatment of multiple diseases. Clin Sci (Lond) (2013) 1.16
Histone deacetylases and mechanisms of regulation of gene expression. Crit Rev Oncog (2015) 1.05
Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans. EMBO J (2010) 1.03
Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues. Oncol Lett (2012) 0.88
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol (2012) 0.88
LSD1 regulates pluripotency of embryonic stem/carcinoma cells through histone deacetylase 1-mediated deacetylation of histone H4 at lysine 16. Mol Cell Biol (2013) 0.87
In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs. J Med Chem (2014) 0.86
HDAC1 and HDAC2 are differentially expressed in endometriosis. Reprod Sci (2012) 0.85
Metabolism, longevity and epigenetics. Cell Mol Life Sci (2013) 0.85
Histones and their modifications in ovarian cancer - drivers of disease and therapeutic targets. Front Oncol (2014) 0.84
Histone deacetylase-3 mediates positive feedback relationship between anaphylaxis and tumor metastasis. J Biol Chem (2014) 0.81
RNA sequencing and transcriptomal analysis of human monocyte to macrophage differentiation. Gene (2013) 0.81
E-cadherin promoter hypermethylation may contribute to protein inactivation in pterygia. Mol Vis (2010) 0.80
Mutagenesis studies of the 14 Å internal cavity of histone deacetylase 1: insights toward the acetate-escape hypothesis and selective inhibitor design. J Med Chem (2014) 0.80
Possible role of autophagy in the treatment of pancreatic cancer with histone deacetylase inhibitors. Cancers (Basel) (2010) 0.79
HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy. Oncoimmunology (2015) 0.78
The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer. Oncotarget (2016) 0.78
Targeting histone deacetylase in lung cancer for early diagnosis: (18)F-FAHA PET/CT imaging of NNK-treated A/J mice model. Am J Nucl Med Mol Imaging (2014) 0.77
Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer. Oncotarget (2016) 0.77
Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci (2017) 0.77
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer. J Cancer Res Clin Oncol (2015) 0.76
Polycistronic tRNA and CRISPR guide-RNA enables highly efficient multiplexed genome engineering in human cells. Biochem Biophys Res Commun (2016) 0.75
Effect of histone deacetylase on prostate carcinoma. Int J Clin Exp Pathol (2015) 0.75
Modulation of microRNA expression in human lung cancer cells by the G9a histone methyltransferase inhibitor BIX01294. Oncol Lett (2014) 0.75
Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review. Gynecol Oncol Rep (2017) 0.75
Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome. BMC Med Genomics (2014) 0.75
Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6. Horm Cancer (2017) 0.75
The role of REST and HDAC2 in epigenetic dysregulation of Nav1.5 and nNav1.5 expression in breast cancer. Cancer Cell Int (2017) 0.75
Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol (2003) 2.18
Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecol Oncol (2009) 2.16
Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest (2003) 1.75
Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol (2007) 1.66
Prefrontal and premotor cortices are involved in adapting walking and running speed on the treadmill: an optical imaging study. Neuroimage (2004) 1.65
BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin Cancer Res (2005) 1.62
Guidelines for obstetrical practice in Japan: Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2011 edition. J Obstet Gynaecol Res (2011) 1.54
Management of retained products of conception with marked vascularity. J Obstet Gynaecol Res (2011) 1.53
Evaluation of sperm head shape at high magnification revealed correlation of sperm DNA fragmentation with aberrant head ellipticity and angularity. Fertil Steril (2013) 1.46
Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol (2010) 1.43
Cervical clamp with ring forceps to prevent prolapse of an intrauterine balloon in the management of postpartum hemorrhage. J Obstet Gynaecol Res (2012) 1.39
Primary retroperitoneal mucinous cystadenoma of borderline malignancy: a case report and review of the literature. Int J Gynecol Pathol (2005) 1.39
Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother (2008) 1.38
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med (2013) 1.38
Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int J Clin Oncol (2009) 1.34
Multimodal assessment of cortical activation during apple peeling by NIRS and fMRI. Neuroimage (2004) 1.32
Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: it's inhibition leads to growth suppression and apoptosis. Cancer Sci (2007) 1.30
Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach. Gynecol Oncol (2003) 1.24
Mutations in the STK11 gene characterize minimal deviation adenocarcinoma of the uterine cervix. Lab Invest (2003) 1.23
Elevated expression of E-cadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Hum Pathol (2004) 1.23
Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol (2004) 1.20
PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res (2013) 1.17
Human amniotic mesenchymal cells have some characteristics of cardiomyocytes. Transplantation (2005) 1.16
Levels of oxidative stress and redox-related molecules in the placenta in preeclampsia and fetal growth restriction. Virchows Arch (2003) 1.13
Human amnion-isolated cells normalize blood glucose in streptozotocin-induced diabetic mice. Cell Transplant (2003) 1.12
Nuclear expression of S100A4 is associated with aggressive behavior of epithelial ovarian carcinoma: an important autocrine/paracrine factor in tumor progression. Cancer Sci (2006) 1.12
Cerebral hemodynamics in newborn infants exposed to speech sounds: a whole-head optical topography study. Hum Brain Mapp (2011) 1.11
A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Jpn J Clin Oncol (2009) 1.11
Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression. Med Mol Morphol (2009) 1.11
Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence. Oncogene (2004) 1.11
Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition. Int J Clin Oncol (2010) 1.09
Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res (2010) 1.08
Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma. Hum Pathol (2005) 1.06
The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int J Cancer (2011) 1.05
Clinical management of atypical polypoid adenomyoma of the uterus. A clinicopathological review of 29 cases. Gynecol Oncol (2013) 1.04
Overexpression of hedgehog signaling molecules and its involvement in the proliferation of endometrial carcinoma cells. Clin Cancer Res (2007) 1.04
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer (2014) 1.03
CT and MR features of struma ovarii. Abdom Imaging (2012) 1.02
Role of platelets in placentation. Med Mol Morphol (2010) 1.02
Prenatal differential diagnosis of complete hydatidiform mole with a twin live fetus and placental mesenchymal dysplasia by magnetic resonance imaging. J Obstet Gynaecol Res (2014) 1.01
Vaginal delivery in the presence of huge vulvar varicosities: a case report with MRI evaluation. Eur J Obstet Gynecol Reprod Biol (2012) 1.00
Premotor cortex is involved in restoration of gait in stroke. Ann Neurol (2002) 1.00
Autocrine stimulation of IGF1 in estrogen-induced growth of endometrial carcinoma cells: involvement of the mitogen-activated protein kinase pathway followed by up-regulation of cyclin D1 and cyclin E. Endocr Relat Cancer (2008) 1.00
Expression of the mitogen-inducible gene-2 (mig-2) is elevated in human uterine leiomyomas but not in leiomyosarcomas. Hum Pathol (2004) 0.99
Leiomyoma of the ovary presenting with Meigs' syndrome. J Obstet Gynaecol Res (2005) 0.98
CD10 is a marker for normal and neoplastic endometrial stromal cells. Int J Gynecol Pathol (2002) 0.98
Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Jpn J Clin Oncol (2008) 0.97
Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases. Int J Clin Oncol (2011) 0.97
Urachal adenocarcinoma metastatic to the ovaries: case report and literature review. Int J Gynecol Pathol (2003) 0.97
Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype. Cancer Lett (2011) 0.97
Histotype-specific copy-number alterations in ovarian cancer. BMC Med Genomics (2012) 0.96
Differential effects of inhibition of bone morphogenic protein (BMP) signalling on T-cell activation and differentiation. Eur J Immunol (2011) 0.96
Cyclic changes in the expression of steroid receptor coactivators and corepressors in the normal human endometrium. J Clin Endocrinol Metab (2003) 0.95
Prognostic significance of Notch signalling molecules and their involvement in the invasiveness of endometrial carcinoma cells. Histopathology (2012) 0.94
Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Sci (2010) 0.93
Hypoxia-induced changes in the expression of VEGF, HIF-1 alpha and cell cycle-related molecules in ovarian cancer cells. Anticancer Res (2003) 0.93
The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin Immunol (2011) 0.93
Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study. Oncol Rep (2009) 0.93
Overexpression of RhoA enhances peritoneal dissemination: RhoA suppression with Lovastatin may be useful for ovarian cancer. Cancer Sci (2008) 0.92
Complement split product C4d deposition in placenta in systemic lupus erythematosus and pregnancy-induced hypertension. Pathol Int (2013) 0.92
Wavelet analysis for detecting body-movement artifacts in optical topography signals. Neuroimage (2006) 0.92
Minimal deviation mucinous adenocarcinoma ('adenoma malignum') of the uterine corpus. Pathol Int (2010) 0.91
Expression of replication-licensing factors MCM2 and MCM3 in normal, hyperplastic, and carcinomatous endometrium: correlation with expression of Ki-67 and estrogen and progesterone receptors. Int J Gynecol Pathol (2003) 0.91
Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy. Sci Rep (2011) 0.91
Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression. Cancer (2003) 0.91
Electrochemotherapy for digital chondrosarcoma. J Orthop Sci (2003) 0.91